ORIC Pharmaceuticals, Inc. ORIC · Stock Open ORIC Pharmaceuticals, Inc. in new tab
Analyst price targets
Recent rating changes, newest first
ORIC Pharmaceuticals, Inc. Analysis (ORIC)
Is ORIC Pharmaceuticals, Inc. a good investment? ORIC Pharmaceuticals, Inc. (ORIC) is currently trading at 12.77 USD. Market analysts have a consensus price target of 21.64 USD. This suggests a potential upside from current levels.
Earnings Schedule: ORIC Pharmaceuticals, Inc. is expected to release its next earnings report on Nov. 12, 2026. The market consensus estimate for Forward EPS is -1.67.
Investor FAQ
Does ORIC Pharmaceuticals, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is ORIC Pharmaceuticals, Inc.?
ORIC Pharmaceuticals, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 12, 2026. The company currently has a trailing EPS of -1.35.
Company Profile
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
Community Discussion